Financial Performance - The group's revenue for the year ended December 31, 2022, was RMB 5,991.84 million, an increase of 10.95% compared to RMB 5,400.49 million in the previous year[3]. - Net profit for the same period was RMB 1,001.62 million, reflecting a growth of 15.55% from RMB 866.84 million year-on-year[3]. - Earnings attributable to the owners of the company reached RMB 582.89 million, up 14.91% from RMB 507.25 million in the previous year[3]. - The basic and diluted earnings per share were RMB 0.46, compared to RMB 0.40 in the previous year[7]. - The company reported a gross profit of RMB 2,591.83 million, with a gross margin improvement driven by effective cost management[7]. - The total comprehensive income for the year was RMB 1,264.81 million, significantly higher than RMB 784.63 million in the previous year[9]. - The total revenue recognized from contract liabilities at the beginning of the year was RMB 222,373 in 2022, significantly higher than RMB 2,078 in 2021[25]. - The company recognized a total annual profit of RMB 1,001,620,000 across its segments for 2022[39]. Assets and Liabilities - Total assets increased to RMB 12,484,768 thousand in 2022, up from RMB 11,593,866 thousand in 2021, representing a growth of approximately 7.7%[10]. - Non-current assets decreased slightly to RMB 3,412,587 thousand in 2022 from RMB 3,463,576 thousand in 2021, a decline of about 1.5%[10]. - Current assets rose significantly to RMB 9,072,181 thousand in 2022, compared to RMB 8,130,290 thousand in 2021, marking an increase of approximately 11.6%[10]. - Total liabilities amounted to RMB 3,467,830 thousand in 2022, compared to RMB 3,435,464 thousand in 2021, reflecting a slight increase of about 0.9%[12]. - Total equity increased to RMB 9,016,938 thousand in 2022, up from RMB 8,158,402 thousand in 2021, indicating a growth of about 10.5%[12]. - Non-current liabilities rose to RMB 1,416,187 thousand in 2022 from RMB 977,334 thousand in 2021, an increase of approximately 44.9%[12]. Research and Development - The company will continue to invest in research and development to innovate and meet the growing health awareness among consumers[5]. - Research and development expenses for 2022 amounted to RMB 78,433, an increase of 60.4% from RMB 48,904 in 2021[28]. - The company is advancing clinical research for new drug projects, including the efficacy evaluation of Jingzhi Niuhuang Jiedu Pian for oral ulcers and Anshen Jiannao Ye for Alzheimer's disease[65]. - The company is also focusing on the safety evaluation and production verification of multiple classic Chinese medicine formulations[65]. Marketing and Sales - The company launched new products including Guanxin Suhe Wan and Jiawei Xiaoyao Wan during the year to enhance production capacity and ensure supply[63]. - The company continues to deepen its marketing strategy through various promotional activities and partnerships with major distributors to drive sales growth[64]. - The company is leveraging e-commerce platforms to enhance sales, utilizing tools like promotional events to boost product visibility and conversion rates[64]. - The sales of the Jin Kui Shen Qi Wan series increased by 1.71%, while the sales of the Ganmao Qingre Granules series grew by 11.00% year-on-year[64]. Corporate Governance - The company has adopted the principles and standards of the Corporate Governance Code as per the Hong Kong Stock Exchange, ensuring robust governance practices[87]. - The audit committee held two meetings in 2022 to review the financial performance and compliance of the company, ensuring adherence to risk management and internal controls[88]. - The company has received annual statements from independent non-executive directors regarding compliance with the October Commitment, confirming no breach of competitive agreements[86]. - The board of directors includes a mix of executive and independent non-executive members, ensuring diverse oversight and governance[90]. Dividends and Shareholder Returns - The cash dividends paid in 2022 were RMB 204,925,000, maintaining the same level as in 2021, with a dividend per share of RMB 0.16[33]. - The company proposed a final cash dividend of RMB 0.16 per share for the year ending December 31, 2022, totaling RMB 204,925,440, subject to approval at the annual general meeting[34]. - The company proposed a final dividend of RMB 0.16 per share for the year ended December 31, 2022, totaling RMB 204,925,440, consistent with the previous year's dividend[60]. Strategic Focus - The company plans to focus on "large variety strategy" to enhance brand, variety, and quality, aiming for high-quality development in the TCM industry[5]. - The company aims to enhance its production capabilities and market responsiveness, focusing on a "big variety strategy" to meet market demands[83]. - The company has established a competitive framework with Beijing Tongrentang Co., Ltd., ensuring no direct competition in product names and formulations, except for the An Gong Niu Huang Wan[84].
同仁堂科技(01666) - 2022 - 年度业绩